Immunitybio Inc
General ticker "IBRX" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $2.8B
Immunitybio Inc follows the US Stock Market performance with the rate: 2.2%.
Estimated limits based on current volatility of 2.1%: low 2.56$, high 2.73$
Factors to consider:
- US accounted for 17.5% of revenue in the fiscal year ended 2022-12-31
- Current price 16.6% below estimated low
- Earnings for 6 months up through Q2 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2023-12-31 to 2025-12-30
- 2023-12-31 to 2024-12-30 estimated range: [3.20$, 8.49$]
- 2024-12-30 to 2025-12-30 estimated range: [2.57$, 6.98$]
Financial Metrics affecting the IBRX estimates:
- Negative: Non-GAAP EPS, $ of -0.93 <= 0.10
- Negative: Operating profit margin, % of -99.83 <= 1.03
- Negative: Operating cash flow per share per price, % of -15.43 <= 2.35
- Negative: negative Net income
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Negative: Industry operating cash flow per share per price (median), % of -23.87 <= 3.85
Short-term IBRX quotes
Long-term IBRX plot with estimates
Financial data
| YTD | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|
| Operating Revenue | $0.93MM | $0.24MM | $0.62MM |
| Operating Expenses | $331.21MM | $351.54MM | $362.87MM |
| Operating Income | $-330.28MM | $-351.30MM | $-362.25MM |
| Non-Operating Income | $-19.56MM | $-65.99MM | $-221.64MM |
| Interest Expense | $14.85MM | $63.52MM | $129.20MM |
| R&D Expense | $195.96MM | $248.15MM | $232.37MM |
| Income(Loss) | $-349.84MM | $-417.29MM | $-583.89MM |
| Taxes | $0.01MM | $0.03MM | $-0.70MM |
| Profit(Loss) | $-349.85MM | $-417.32MM | $-583.20MM |
| Stockholders Equity | $-242.17MM | $-447.33MM | $-586.99MM |
| Inventory | $0.00MM | $26.35MM | $0.00MM |
| Assets | $468.91MM | $362.36MM | $504.45MM |
| Operating Cash Flow | $-274.42MM | $-337.51MM | $-366.76MM |
| Capital expenditure | $33.56MM | $99.39MM | $30.58MM |
| Investing Cash Flow | $-84.89MM | $27.30MM | $-30.47MM |
| Financing Cash Flow | $505.44MM | $233.61MM | $558.34MM |
| Earnings Per Share* | $-0.90 | $-1.04 | $-1.15 |
* EPS are Split Adjusted, recent splits may be reflected with a delay.